|
Clinical characteristics
|
|
Female: n (%)
|
13 (72.2)
|
19 (79.2)
|
–
|
|
Age: median (range)
|
63 (24–80)
|
65.5 (27–82)
|
–
|
|
Radio-induced: n (%)
|
7 (38.9)
|
12 (50)
|
–
|
|
Superficial: n (%)a
|
11 (61.1)
|
16 (66.7)
|
–
|
|
Grade 2 or 3: n (%)
|
10 (55.6)
|
13 (54.2)
|
–
|
|
Metastatic: n (%)
|
12 (66.7)
|
16 (66.7)
|
–
|
|
Prior exposure to anthracycline: n (%)
|
8 (44.4)
|
8 (33.3)
|
–
|
|
Performance status (WHO) = 0: n (%)b
|
10 (58.8)
|
13 (54.2)
|
–
|
|
Baseline biomarkers (D1)
|
|
Human FGF (pg/mL): mean (sd)
|
5.6 (2.1)
|
6.0 (3.5)
|
0.72
|
|
PlGF (pg/mL): mean (sd)
|
24.7 (17.2)
|
17.8 (10.2)
|
0.12
|
|
SCF sR/c-kit (ng/mL): mean (sd)
|
8.9 (2.5)
|
8.2 (2.6)
|
0.35
|
|
sE-Selectin (ng/mL): mean (sd)
|
33.7 (18.5)
|
44.8 (24.9)
|
0.08
|
|
TSP-1 (μg/mL): mean (sd)
|
54.9 (17.3)
|
44.9 (21.6)
|
0.17
|
|
VEGF (ng/mL): mean (sd)
|
0.44 (0.28)
|
0.55 (0.39)
|
0.38
|
|
VEGF-C (ng/mL): mean (sd)
|
4.2 (1.5)
|
4.4 (1.7)
|
0.70
|
